News

Oncology Nursing News22h
ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC
The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...